Resources
The resources hub provides patients, families, and healthcare providers with access to educational tools, support materials, and study information designed to help you better understand our clinical programs and ongoing work in Developmental Epileptic Encephalopathies.
Information Sheets
Below you will find information sheets on each of the clinical trials currently enrolling.
EMBOLD
(relutrigine)
EMBRAVE 3
(elsunersen)
EMERALD
(relutrigine)
Resilience Motor Seizure Guide
Perspectives From Parents & Advocates
Hear from parents and advocates about clinical trials and how they are helping families and their hope for the future.
Window of Hope
Families’ Experiences With the EMBOLD Study
SCN2A Advocacy Groups Around the World Coming Together to Spread Awareness and Drive Treatments for SCN2A-Related Disorders
Press Releases
September 3, 2024
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
July 17, 2025
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Links to Our Studies on ClinicalTrials.gov
Study
Sponsorship Request Form
We welcome partnership opportunities with advocacy groups that align with our mission. If your organization is looking for sponsorship, please share your request with us through the form below.
